Tanezumab (CAS 880266-57-9) Market Research Report 2016

Date: October 15, 2016
Pages: 70
US$ 2,650.00 US$ 2,200.00 (This month only)
License [?]:
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: T2023266D9BEN

Download PDF Leaflet

Tanezumab (CAS 880266-57-9) Market Research Report 2016

Tanezumab (CAS 880266-57-9) Market Research Report 2016 aims at providing comprehensive data on tanezumab market globally and regionally (Europe, Asia, North America, Latin America etc.)

The report includes tanezumab description, covers its application areas, manufacturing methods, patents. It captures tanezumab market trends, pays close attention to tanezumab manufacturers and names suppliers.

Besides, the report provides tanezumab prices in regional markets.

In addition to the above the report determines tanezumab consumers.

Our research team can evaluate the following market characteristics for each chemical product in any country or region:

  • current market situation
  • plants’ capacity and production
  • consumption volume and structure
  • export and import
  • market prices trends
  • existing technologies an patents
  • raw materials market
  • future market development
  • etc.
Thus, Tanezumab (CAS 880266-57-9) Market Research Report 2016 can feature:
  • tanezumab ranges, trademarks, analogous products, application areas, manufacturing methods
  • present tanezumab market conditions, prices
  • tanezumab market forecast, estimations
  • tanezumab manufacturers, consumers and traders (including contact details)

Tanezumab (CAS 880266-57-9) Market Research Report 2016 contents were worked out and placed on the website in October, 2016. As a special offer the report price was cut and now is as low as US$ 2,200.00. Do not lose the chance to order this Market Report for almost half-price.

1. TANEZUMAB (CAS 880266-57-9)

1.1. General information, synonyms
1.2. Composition, chemical structure
1.3. Safety information
1.4. Hazards identification
1.5. Handling and storage
1.6. Toxicological & ecological information
1.7. Transport information


2.1. Tanezumab application spheres, downstream products



Summary of the invention
Detailed description of the invention


5.1. General tanezumab market situation, trends
5.2. Manufacturers of tanezumab
  - Europe
  - Asia
  - North America
  - Other regions
5.3. Tanezumab suppliers (importers, local distributors)
  - Europe
  - Asia
  - North America
  - Other regions
5.4. Tanezumab market forecast


6.1. Tanezumab prices in Europe
6.2. Tanezumab prices in Asia
6.3. Tanezumab prices in North America
6.4. Tanezumab prices in other regions


7.1. Tanezumab market by application sphere
7.2. Tanezumab downstream markets trends and prospects
7.3. Tanezumab consumers globally
  - Europe
  - Asia
  - North America
  - Other regions

*Please note that Tanezumab (CAS 880266-57-9) Market Research Report 2016 is a half ready publication and contents are subject to change. It only requires updating with the help of new data that are constantly retrieved from Publisher’s databases and other sources. This updating process takes 3-5 business days after order is placed. Thus, our clients always obtain a revised and updated version of each report. Please also note that we do not charge for such an updating procedure. BAC Reports has information for more than 25,000 different chemicals available but it is impossible to have all reports updated immediately. That is why it takes 3-5 days to update a report after an order is received.
Tanezumab is a monoclonal antibody against nerve growth factor (NGF), with a molecular formula of C6464H9942N1706O2026S46. It was developed by the American corporation Pfizer as a pain mediator.

Tanezumab is used to reduce pain in joints and improves their functions. The drug reduces the intensity of low back pain, and it has only a few slight side effects such as headaches, cold-like symptoms and paresthesias. Tanezumab is also useful as a treatment for bone cancer pain, by neutralizing NGF activity.

The drug is combustible at high temperatures, and therefore should be handled within an established safety program.

Tanezumab should be stored in a tightly closed container in cool, dry and ventilated areas. One should avoid skin contact with tanezumab and breathing its vapour.

Tanezumab is covered in the study Tanezumab (CAS 7440-02-0) Market Research Report 2016. The report encompasses proper description of the product, unveils application areas, and briefly summarizes patents in the sphere. It overlooks tanezumab market situation, names manufacturers, suppliers as well as users. The report also provides current tanezumab prices.
Skip to top

Ask Your Question

Tanezumab (CAS 880266-57-9) Market Research Report 2016
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: